Search academic texts

Information × Registration Number 0222U000782, 0120U103333 , R & D reports Title Development of cardiomyogenic fibroblast reprogramming technology using CRISPR-Cas9 system as a potential method of improving heart function after heart attack popup.stage_title Head Piven Oksana O., Кандидат біологічних наук Registration Date 18-01-2022 Organization Institute of Molecular Biology and Genetics of NAS of Ukraine popup.description2 During the reporting period, the creation of a plasmid library expressing candidates for RNA control candidates for the CRISPR system and targeting the promoter regions of the cardiogenesis genes GATA4, MEF2C, TBX5, HAND2 MYOD1 was completed. Restriction analysis of such plasmids was performed. The method of obtaining human mesenchymal stem cells from wharton's jelly has been developed. Their immunophenotyping was performed. The liposomal method of MSC transfection was developed and the efficiency of transfection was evaluated. The expression of fusion of Cas9-VPR proteins in transfected human cells was analyzed, its intracellular localization shows the expression of ZsGreen reporter protein. The in vitro efficacy of our collection of plasmids expressing onRNA targeting the MYOD1 gene was confirmed. In general, we have obtained the necessary and logical basis for the study of the prospects of using the CRISPR system for reprogramming cells for therapeutic purposes. Keywords CRISPRa, CRISPR / Cas9, GATA4, MEF2C, TBX5, HAND2 MYOD1, reprogramming, cardiomyogenic transcription factors   Product Description popup.authors Matsevych Larysa Leonidivna Ruban Tetyana P. Sklyarenko Yuliya V Toporova Olena K. popup.nrat_date 2022-03-09 Close